News & Events

11.13.12 Cardioxyl Pharmaceuticals Raises $28 Million in Series B Financing Led by OrbiMed Advisors

04.04.11 Cardioxyl Pharmaceuticals Presents Data on its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session

08.26.10 Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIA Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients

08.02.10 Cardioxyl Pharmaceuticals Announces Positive Results from First Clinical Study of its Lead Therapy, CXL-1020, in Heart Failure Patients

04.01.10 Cardioxyl Pharmaceuticals' Data Presented at American College of Cardiology (ACC) Annual Scientific Sessions

11.18.09 Cardioxyl Pharmaceuticals announces pre-clinical results on lead clinical candidate, CXL-1020 at American Heart Association Scientific Sessions 2009

10.29.09 Cardioxyl Pharmaceuticals announces late-breaker at American Heart Association Conference

09.15.09 Cardioxyl Pharmaceuticals presents new data at the 13th annual Scientific Meeting of the Heart Failure Society of America

09.10.09 Cardioxyl Pharmaceuticals to present data at two cardiology conferences

07.01.09 Cardioxyl Pharmaceuticals initiates phase I/IIa study in heart failure

Nitroxyl Technology

Cardioxyl has developed proprietary expertise in the biology, physiology and chemistry of nitroxyl donors

View More

Our Mission

Cardioxyl's mission is to realize the potential of nitroxyl technology through the development of novel therapies that improve the health and quality of life of patients with serious cardiovascular disease.